Pharmigene, Inc. (TPEX:7595)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
10.00
+0.10 (1.01%)
Apr 29, 2026, 2:00 PM CST
-18.70%
Market Cap 499.60M
Revenue (ttm) 149.25M
Net Income (ttm) -75.51M
Shares Out 50.47M
EPS (ttm) -1.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,007
Average Volume 44,848
Open 9.90
Previous Close 9.90
Day's Range 9.90 - 10.00
52-Week Range 9.35 - 14.10
Beta 0.05
RSI 46.57
Earnings Date Mar 27, 2026

About Pharmigene

Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers molecular diagnostics to test adverse drug reactions; and DNA extraction products for gene expression analysis, clinical molecular diagnosis, human identity testing, forensics, and biomedical research applications. The company also provides pharmacogenomics test, drug allergy test, and functional medicine test services. In addition, it distributes various genomics and genetics equipment and reagents; and provides professional co... [Read more]

Sector Healthcare
Founded 1994
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 7595
Full Company Profile

Financial Performance

In 2024, Pharmigene's revenue was 116.53 million, a decrease of -12.19% compared to the previous year's 132.71 million. Losses were -82.86 million, 14.1% more than in 2023.

Financial Statements

News

There is no news available yet.